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Neurotrophin receptors mediate a plethora of signals affecting neuronal survival. The
p75 pan-neurotrophin receptor controls neuronal cell fate after its selective activation
by immature and mature isoforms of all neurotrophins. It also exerts pleiotropic effects
interacting with a variety of ligands in different neuronal or non-neuronal cells. In the
present study, we explored the biophysical and functional interactions of a blood-
brain-barrier (BBB) permeable, C17-spiroepoxy steroid derivative, BNN27, with p75NTR
receptor. BNN27 was recently shown to bind to NGF high-affinity receptor, TrkA.
We now tested the p75NTR-mediated effects of BNN27 in mouse Cerebellar Granule
Neurons (CGNs), expressing p75NTR, but not TrkA receptors. Our findings show that
BNN27 physically interacts with p75NTR receptors in specific amino-residues of its
extracellular domain, inducing the recruitment of p75NTR receptor to its effector protein
RIP2 and the simultaneous release of RhoGDI in primary neuronal cells. Activation of
the p75NTR receptor by BNN27 reverses serum deprivation-induced apoptosis of CGNs
resulting in the decrease of the phosphorylation of pro-apoptotic JNK kinase and of the
cleavage of Caspase-3, effects completely abolished in CGNs, isolated from p75NTR null
mice. In conclusion, BNN27 represents a lead molecule for the development of novel
p75NTR ligands, controlling specific p75NTR-mediated signaling of neuronal cell fate, with
potential applications in therapeutics of neurodegenerative diseases and brain trauma.
Keywords: p75 neurotrophin receptor, DHEA, nerve growth factor (NGF), neurotrophin receptors signaling,
neuronal apoptosis, steroid, STD NMR, molecular dynamics
Abbreviations: BDNF, brain-derived neurotrophic factor; BNN27, C17-spiroepoxy analog of DHEA; CHO, Chinese hamster
ovary cell line; CYP17, cytochrome P450 17-hydroxylase/17,20-lyase; DHEA, dehydroepiandrosterone; ECD, extracellular
domain; ERK, extracellular signal-regulated kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HEK293, human
embryonic kidney cell line 293; JNK, c-Jun N-terminal kinase; MEFs, mouse embryonic fibroblasts; NGF, nerve growth factor;
NT-3, neurotrophin-3; p75KO, p75 receptor knockout; p75NTR, p75 neurotrophin receptor; PC12, pheochromacytoma cells;
PEG-BNN27, polyethylene glycol amino resin-supported BNN27; RhoGDI, Rho GDP dissociation inhibitor; RIP2, receptor-
interacting protein 2; STD NMR, saturation transfer difference nuclear magnetic resonance; TRAF6, TNF receptor-associated
factor 6; Trk, tropomyosin related kinase; wt, wild type.
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INTRODUCTION
Neurotrophic factors (NGF, BDNF and NT3/4) are
large polypeptidic, secreted molecules that exert potent
neuroprotective and neurogenic effects (Chao, 2003; Lu et al.,
2005). Mature neurotrophins preferentially and selectively bind
and activate the Trk receptors (Teng and Hempstead, 2004)
while all members of neurotrophin family can also -albeit with
lower affinity- bind to pan-neurotrophin p75 receptor. It is of
note that neurotrophin immature isoforms (pro-neurotrophins)
show high selectivity for p75NTR (Lee et al., 2001; Dechant
and Barde, 2002; Gentry et al., 2004; Nykjaer et al., 2004).
The p75NTR receptor is a member of the Tumor Necrosis
Family Receptors (TNFR) superfamily and is mainly expressed
during nervous system development but also after injury or
degeneration of neuronal and glial cells (for a review, see Ibáñez
and Simi, 2012). Despite the pro-apoptotic role of p75NTR,
there is growing evidence that this receptor can also promote
survival in specific types of neurons and other cells (DeFreitas
et al., 2001; Massa et al., 2006; Meeker and Williams, 2015). The
pro-survival effects of p75NTR are largely dependent upon the
operative ligands and the co-expression of other receptors that
interact with p75NTR, like Trks or Sortilin (DeFreitas et al., 2001;
Chao, 2003; Nykjaer et al., 2004). More specifically, activation
of the transcription factor NFkappaB upon the recruitment of
RIP2 protein to p75NTR, leads to survival signals on specific
neurons (Carter et al., 1996; Vicario et al., 2015), while it
simultaneously induces the release of RhoGDI from the receptor
and the subsequent RhoA inactivation (Charalampopoulos et al.,
2012). These p75NTR-mediated survival-signaling cascades are
largely dependent upon mature neurotrophin binding to the
receptor. On the contrary, the p75NTR-dependent regulation
of cJun/JNK phosphorylation effectively induces cell death,
although not as effectively as Caspase-3 (Bhakar et al., 2003).
Cell death signals that originate from p75NTR have been recently
associated to other co-receptors, like sortilin, SorCS2 and SorL1
(members of the Vps10 family) (Nykjaer et al., 2004; Nykjaer and
Willnow, 2012), and they are selectively activated upon binding
of pro-neurotrophins to p75NTR. Furthermore, a plethora of
other ligands can directly interact with p75NTR receptors, such
as Aβ-amyloid, myelin associated glycoprotein (MAG) or Nogo,
leading to differential signaling in a cell-context manner (Wang
et al., 2002; Wong et al., 2002; Yaar et al., 2002; Knowles et al.,
2009).
We have previously reported that neurosteroid DHEA,
produced by neurons, glia and the adrenals, binds to all Trk and
p75NTR receptors with Ki at nanomolar concentrations (Lazaridis
et al., 2011; Pediaditakis et al., 2015), inducing cell survival
(Charalampopoulos et al., 2004, 2008). DHEA can also activate
classical steroid receptors, such as Androgen Receptor (AR) or
Estrogen Receptors (ERα and ERβ), as well as a number of
neurotransmitter receptors (Maurice et al., 2000; Chen et al.,
2005). We have recently developed a novel C17-spiroepoxy
analog of DHEA, BNN27, which selectively binds to and activates
the NGF receptor TrkA, but not TrkB or TrkC (Pediaditakis et al.,
2016). Modifications on C17 of BNN27 abolish its susceptibility
to metabolic enzymes that convert DHEA to androgens or
estrogens. Additionally, BNN27 has been shown to penetrate
blood-brain-barrier (Bennett et al., 2016) and to not interact
with AR or ERs in in vitro studies (Calogeropoulou et al., 2009;
Pediaditakis et al., 2016).
The aim of the present study was to explore the ability of
BNN27 to interact and activate the pan-neurotrophin p75NTR
receptors. We tested its biological effects in Cerebellar Granule
Neurons (CGNs) of wt and p75NTR null mice, an established cell
model for the study of p75NTR signaling. Indeed, CGNs express
p75NTR receptors and not the high affinity receptor for the NGF,
TrkA (Courtney et al., 1997). They also express TrkB and TrkC
receptors, providing the optimal substrate for evaluating the
effects of other neurotrophins (BDNF and NT-3) compared to
NGF. Cultured in the presence of serum, CGNs survive and
show mature neuronal phenotype (Gallo et al., 1987; Balázs et al.,
1988) Upon neurotrophin stimulation in serum-deprivation
conditions, CGNs respond to survival signals: BDNF and NT-3
seem to rescue the cells through their specific Trk receptors, while
NGF is inducing anti-apoptotic signals through the activation of
p75NTR (Minichiello and Klein, 1996; Courtney et al., 1997). We
also evaluated the ability of BNN27 to interact with and activate
p75NTR receptors, focusing on the exact post-receptor cellular
mechanisms by which it affects NGF-sensitive cell signaling,
related to neuronal cell fate. Several physicochemical methods
(NMR and pull-down assays with recombinant p75NTR) were
also used to clarify the molecular interactions of BNN27 with
p75NTR receptors. Based on our findings we propose BNN27
as an effective lead molecule for the development of novel
p75NTR ligands, controlling specific p75NTR-mediated signaling
of neuronal cell fate, with potential applications in therapeutics
of neurodegenerative diseases and brain trauma.
MATERIALS AND METHODS
Plasmids, Antibodies and Proteins
Plasmids expressing p75NTR, TrkA and TrkB were previously
described Lazaridis et al. (2011) and Pediaditakis et al. (2015).
p751ECD and p75C257A constructs were previously described by
Jung et al. (2003) and Vilar et al. (2009), respectively. Normal
expression of all constructs was verified by immunoblotting.
The origin of antibodies was as follows: RIP2 (Cat. No. ADI-
AAP-460; Enzo Life Sciences Farmingdale), RhoGDI (Cat. No.
R3025; Sigma), p75NTR for blotting [IB] (Cat. No. G3231;
Promega), MC192 anti-p75NTR for immunoprecipitation [IP]
(Cat. No. MAB365R; Millipore), TrkA (Cat. No. 06-574;
Millipore), TrkB (Cat. No. 4606; Cell Signaling), phospho-
JNK (Cat. No. 4668; Cell Signaling), JNK (Cat. No. 9252; Cell
Signaling), cleaved Caspase-3 (Cat. No. 9661; Cell Signaling);
actin (Cat. No. A4700; Sigma). Secondary antibodies: horseradish
peroxidase-conjugated anti-rabbit IgG (Cat. No. 65-6120;
Invitrogen) and horseradish peroxidase-conjugated anti-mouse
IgG (Cat. No. AP-124P; Millipore). Anti-rabbit-R-phycoerythrin
conjugated (Cat. No. P9537; Sigma), anti-mouse-fluorescein
conjugated (Cat. No. AP124F; Millipore), anti-rabbit Alexa
Fluor 488 (Cat. No. A21206; Invitrogen), anti-rabbit Alexa
Fluor 546 (Cat No. A10040; Invitrogen). NGF (Cat. No.
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01-125) was purchased from Millipore. BDNF (Cat. No.
P3595) and NT3 (Cat. No. P4433) were purchased from
Novus.
Animals
p75NTR knockout mouse strain was obtained from Jacksons
Laboratory (Lee et al., 1992) and maintained on a 12 h
light/dark cycle with ad libitum access to food and water.
Adult het mice were crossed and postnatal day 6 WT
and KO pups were used for the isolation of cerebella
after euthanasia in a CO2 chamber. Animal experimentation
received the approval of Veterinary Directorate of Prefecture
of Heraklion, Crete and was carried out in compliance with
Greek Government guidelines and the guidelines of our ethics
committee.
Cell Culture
HEK293 cells were obtained from LGC Promochem and cultured
under specific conditions for each cell line. MEFs were kindly
provided from Dr C.F. Ibáñez (Karolinska Institutet) and
cultured under standard conditions. HEK293 and MEF cells were
transfected with the appropriate p75NTR plasmids (wt, 1ECD,
C257) by using TurboFect (Cat. No. R0531; Thermo Scientific,
Rockford, IL, USA) according to manufacturer’s instructions.
Transfected cells were typically used on the second day after
transfection.
Primary Cerebellar Granule Neurons
Culture
Cerebellar granule neuron cultures were prepared as described
previously, with some modifications (Selvakumar and Kilpatrick,
2013). Briefly, the cerebella of postnatal day 6 (P6) wt and
p75NTR-knockout mice were isolated and digested with 0.25%
trypsin (Sigma) for 15 min at 37◦C. The enzyme was deactivated
by adding DMEM/F12 (Sigma) medium containing 10% FBS
(Gibco). The excess medium was removed and the remaining
tissue was dissociated with 1 ml of culturing medium using
the 1 ml pipette until cloudy. The cell suspension was filtered
through a nylon mesh (pore size 70µm) to remove any remaining
big chunk of tissue. To obtain a culture enriched in CGNs the
cell suspension was loaded onto a step gradient of 35 and 60%
Percoll (GE Healthcare) and centrifuged at 1800 g for 20 min at
room temperature. The upper interface was removed (containing
astroglia, Purkinje cells and interneurons) and the interface,
which contains the CGNs, was transferred to a 15 ml falcon
tube. For extra enrichment the collected cell suspension was
plated on poly-D-lysine coated petri dish for 20 min in a 5%
CO2, 37◦C incubator. Remaining astroglia adhere to the plate
whereas granule neurons float. The supernatant was collected
from the plate, centrifuged and re-suspended in the desire volume
of the culturing DMEM/F12 medium supplemented with 2%
B27 Supplement (Gibco), 0.6% D-glucose (Sigma), 1% GlutaMax
(Gibco), 1% Penicillin/ Streptomycin (Gibco) and 250 µM KCl.
Either half or 1/4 cerebellum was plated per well of a 12-well plate
and 24-well plate, respectively.
Immunoprecipitation and Western Blot
MEF cells were incubated with BNN27 (100 nM), DHEA
(100 nM), NGF (100 ng/ml), E2 (100 nm) in the presence of
serum free, washed twice with ice-cold PBS, and suspended
in 400 µL cold lysis buffer containing 1% Nonidet P-40,
20 mM Tris (pH 7.4), and 137 mM NaCl, supplemented with
protease inhibitors. Cleared lysates were pre-adsorbed with
protein A-Sepharose beads (Amersham, Piscataway, NJ, USA)
for 1 h at 4◦C and IP with anti-p75NTR overnight at 4◦C.
Protein A-Sepharose beads were incubated with the lysates
for 2–4 h at 4◦C with gentle shaking. For immunoblot (IB)
analysis, the beads were suspended in sodium dodecyl sulfate-
loading buffer and separated by SDS-PAGE. Proteins were
transferred to nitrocellulose membranes and blotted with the
corresponding antibodies. Then, the membranes were imaged
with the ChemiDoc MP imager (Bio-Rad). ImageLab software
version 4.1 (Bio-Rad) was used for image acquisition and
densitometric analysis of the blots.
Binding Assay
HEK293 cells were transfected with the cDNA expression
plasmids coding for p75NTR or p751ECD. Western blot inserts
show the efficacy of transfection. Crude membrane fractions
were isolated by differential centrifugation at 2,500 g (10 min at
4◦C to remove unbroken cells and nuclei) and 100,000 g (1 h,
at 4◦C). A constant concentration of [3H]-DHEA (5 nM) was
incubated with increasing concentrations of BNN27 (from 10−12
to 10−6 M) in a final volume of 100 µl for 18 h at 4◦C. Bound
[3H]-DHEA was measured in scintillation fluid (SigmaFluor,
Sigma) in a scintillation counter (Perkin Elmer, Foster City, CA,
USA) with 60% efficiency for tritium.
Pull Down and Saturation Transfer
Difference (STD-NMR) Studies
Synthesis of BNN27 Conjugated to NovaPEG Amino
Resin
BNN27 conjugated to NovaPEG amino resin was synthesized as
previously described Pediaditakis et al. (2016).
STD-NMR Experiments
The recombinant mouse NGFR/TNFRSF16-Fc chimera (also
named p75 neurotrophin receptor) comprising the mouse NGFR
ECD were purchased by R&D Systems, Inc. NGF (NGF 2.5S,
mouse) was purchased by Millipore. D2O 99.9% from Euriso-Top
was used for the PBS buffer.
NMR samples were prepared in Shigemi NMR tubes using
D2O (99.9%) PBS buffer, pD = 7.4. The solutions of p75/BNN27
and NGF/BNN27 were prepared using a protein concentration
of 0.6 µM and a ligand concentration of 60 µM, resulting in
protein:ligand ratio of 1:100. Successive additions of NGF were
applied to the solution of p75NTR/BNN27 at 1:1 up to 1:20
molar ratios of p75NTR:NGF. NMR spectra were acquired on a
Agilent (Varian) 600 MHz NMR spectrometer at 25◦C using a
1H{13C/15N} 5 mm PFG Automatable Triple Resonance probe.
Experiments were run using the pulse sequences provided by
the Varian BioPack library. The 1H STD NMR experiments
Frontiers in Pharmacology | www.frontiersin.org 3 December 2016 | Volume 7 | Article 512
fphar-07-00512 December 22, 2016 Time: 15:54 # 4
Pediaditakis et al. Microneurotrophin BNN27 Activates p75NTR Receptor
were recorded with a spectral width of 12019 Hz, 8192 complex
data points, and 4000 scans. Selective on-resonance irradiation
frequency was set to −0.79 ppm for p75 and −0.94 ppm for
NGF and the off-resonance irradiation frequency was applied at
30 ppm. The saturation scheme consisted of a train of 50 ms
Gauss-shaped pulses separated by a 0.1 ms delay with total
duration of 2.5 s. Subtraction of the on-resonance and off-
resonance spectra was performed internally via phase cycling.
Water suppression was achieved with excitation sculpting.
Control spectra were recorded under identical conditions on
samples containing only BNN27 to test for artifacts. The STD
amplification factor was obtained by averaging the respective
STD amplification factors for the C18 and C19 methyl group
peaks of BNN27 in the studied solutions. The STD amplification
factor is calculated according to the formula:
STD amplification factor = (I0 − Isat)/I0 × ligand excess
where (I0−Isat) corresponds to the STD intensity of one
resonance signal and I0 is the corresponding intensity obtained
from the off resonance spectrum or reference spectrum.
In silico Modeling of BNN27 to p75NTR
The crystal complexes p75NTR/NGF 1:2 (pdb: 1SG1) and
p75NTR/proNGF 2:2 (pdb: 3IJ2) were used for the molecular
modeling studies. The crystal structure of p75NTR dimeric
complex with proNGF resolves the binding of the C-terminal
mature region of mouse proNGF with p75NTR ectodomain. Nine
mutations were introduced at the mature proNGF monomers,
namely, R9M, M37T, G40A, K50R, D60A, P61S, D65E, M92T,
G94E, in order to model human-NGF in the p75NTR/proNGF 2:2
crystal structure (Supplementary Figure 5).
Binding site prediction was performed by applying SiteMap
algorithm, Schrödinger Suite 2013, at the p75NTR monomer (as
obtained from pdb:1SG1 after removing NGF homodimer) and
at the dimeric p75NTR complexed with the modified proNGF, as
described above.
The interactions of an ensemble of BNN27 molecules were
investigated through Molecular Dynamics (MD) simulations in
the cases of: p75NTR alone (30 and 50 ns), p75NTR/NGF complex
(200 ns) and the modified p75NTR/proNGF heterodimeric
complex (150 ns).
Molecular Dynamics Simulations were performed with
Schrodinger 3.8 using the OPLS3 force field. Each modeled
system was solvated in an orthorhombic simulation buffer box
of size 20 Å in each direction with TIP4P water molecules
and the appropriate number of sodium counter-ions, randomly
distributed in the aqueous phase. Before the production run, the
model system was relaxed through a series of minimizations and
short MD simulations were performed using Desmond default
values. Production runs were performed in the NPT ensemble
at 300 K and 1.01325 bar with periodic boundary conditions.
The RESPA integrator was used with time step 2 fs for bonded
and short-range interactions and 6 fs for long-range interactions.
During equilibration the Berendsen thermostat and barostat were
applied with coupling time constants of 100 ps and 1000 ps,
respectively. The cutoff distance for the Coulombic interactions
was set to 9 Å, while the long-range Coulombic interactions were
calculated using the smooth Particle Mesh Ewald (PME) method
with a tolerance of 1e-09.
Cell Death Assay
BNN27 (100 nM), NGF (100 ng/ml), or BDNF (100 ng/ml)
were added to cultures after 6 days CGNs in vitro and kept for
an additional 16 h. During this period, CGNs were switched
to KCl-free and serum-free medium. Finally, the culture was
fixed with 4% Paraformaldehyde (PFA), permeabilised with 0.3%
triton and blocked for non- specific epitopes with 5% Horse
Serum (HS). Staining for β- tubulin+ was performed prior
to TUNEL staining. The primary antibody (Cat. No. 801201,
Biolegend) was incubated overnight at 4◦C and the secondary
anti-rabbit Alexa Fluor 488 (Cat. No. A21206; Invitrogen) for
1 h at RT. Subsequently, TUNEL was assessed using a kit from
Roche following the manufacturer’s instructions and cultures
were analyzed using a fluorescent Zeiss microscope. The number
of TUNEL-positive cells co- localized with b-tubulin staining
(yellowish nucleus) in each culture was counted using an
objective (x40) from 10 visual fields for every condition. The
percentage of TUNEL+ β- tubulin+/β- tubulin+ was calculated
and the mean number was estimated for each condition from
three independent experiments.
RhoA Activity
RhoA activity was evaluated after 30 min neurotrophin
stimulation using the RhoA G-Lisa kit from Cytoskeleton.
Statistical Analysis
All results are reported as the mean ± SEM. Comparison of
two groups was performed using an unpaired t-test. Statistical
analyses were performed using GraphPrism, version 6 (GraphPad
Software Inc.). A P-value of less than 0.05 was considered
significant.
Study Approval
All mouse experiments were approved by the Ethics Committee
of the University Hospital of Heraklion, University of Crete,
Faculty of Medicine and the Ethics Committee of the FORTH.
RESULTS
BNN27 Directly Binds to p75NTR
Receptors
Firstly, we examined the ability of BNN27 to bind to p75NTR
receptor, performing heterologous competition binding assays,
using tritiated DHEA. BNN27 effectively displaced the bound
[3H]-DHEA on membranes isolated from HEK293p75NTR
transfectants (Ki: 3.9 ± 1.2 nM; Figure 1A). To evaluate the
exact domains of p75NTR required for BNN27 binding, we
performed competition assays using membranes from HEK293
cells transfected with the p75NTR mutant, lacking the entire
ECD (with a smaller size as shown by immunoblot assays,
Figure 1A, right panel), necessary for NGF binding (Jung
et al., 2003). Our results showed that BNN27 was unable to
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FIGURE 1 | BNN27 binds directly to p75NTR receptor. (A) Competition binding assays of [3H]-DHEA in the presence of increasing concentrations of BNN27,
using membranes isolated from HEK293 cells transfected with the cDNAs of full-length p75NTR or ECD-truncated p75NTR1ECD receptors (Ki: mean ± SEM of five
independent experiments). Right panel depicts efficacy of transfection, assessed by Western blots. (B) Immobilized BNN27 pulls down p75NTR receptor. Covalently
linked BNN27-7-O-(carboxymethyl) oxime (BNN27-7-CMO) to polyethylene glycol amino resin (NovaPEG amino resin) was incubated with recombinant p75NTR
proteins, then centrifuged. Precipitation experiments show Western blot analysis of pellets and supernatants with specific antibodies against p75NTR proteins, as
described in Section “Materials and Methods.” (C, i) STD-NMR revealed the interaction between BNN27 and p75NTR, further amplified upon NGF additions. No
interaction of BNN27 with NGF alone was observed as suggested by the null STD amplification. (ii,iii) 1H STD-NMR and the corresponding STD-reference spectra.
The binding of BNN27 at p75NTR is evidenced by the presence of BNN27 methyls (18, 19) at the STD spectra; their absence in the case of NGF indicates the lack of
BNN27-NGF interaction.
bind to membranes isolated from HEK293p75NTR1ECD mutants
(Figure 1A), suggesting that the presence of the ECD is necessary
for its binding to the receptor (Figure 1A).
We next assessed whether BNN27, covalently immobilized
on NovaPEG resin, is able to bind directly to recombinant
p75NTR, performing pull-down assays. Precipitation experiments
and western blot analysis of precipitates with specific antibody
against p75NTR showed that immobilized BNN27 (BNN27-
NovaPEG) effectively precipitated recombinant p75NTR proteins,
found in the pellet (Figure 1B). In contrast, there was no
Frontiers in Pharmacology | www.frontiersin.org 5 December 2016 | Volume 7 | Article 512
fphar-07-00512 December 22, 2016 Time: 15:54 # 6
Pediaditakis et al. Microneurotrophin BNN27 Activates p75NTR Receptor
precipitation of recombinant p75NTR in the absence of BNN27
(using only NovaPEG) (Figure 1B; the trace amount of p75NTR
seen in the pellet is due to residual supernatant). We also
monitored the binding of BNN27 to p75NTR by 1H STD-
NMR spectroscopy. The presence of BNN27 resonance peaks
(19Me and 18Me) in the STD spectrum (Figure 1C, ii) clearly
reveals that BNN27 interacts with the recombinant p75NTR
receptor. On the other hand, the lack of the corresponding
resonances in the NGF solution (Figure 1C, iii) indicates that
BNN27 does not interact with the neurotrophin alone. The
addition of NGF to the p75NTR solutions induced an increase
of the BNN27 STD amplification in a concentration dependent
manner (Figure 1C, i). This behavior prompts to the assumption
of p75NTR/NGF gradual complexes formation in solution and
evidences an enhancement of BNN27 binding at the heteromeric
complex.
In silico Studies of BNN27 Interactions
With p75NTR Receptors
It has been proposed that the functional profile of p75NTR is
related with the dimerized conformation of the receptor (Gong
et al., 2008; Vilar et al., 2009). Our in silico strategy was driven
by the absence of crystallographic data of the dimeric form of
p75NTR receptor in complex with the NGF homodimer. Thus,
we have utilized the two most relevant crystal structures, the
asymmetric complex with NGF (pdb:1SG1) and the symmetrical
one with proNGF (pdb:3IJ2) modified accordingly to model
NGF. Five potential binding sites were identified at the p75NTR
monomer as obtained after removing the NGF homodimer from
the crystal complex 1SG1 (Supplementary Figure 1). Among
them, only one (site 5), was probed by MD simulations as the
most potent to stabilize interactions with BNN27. Site 5 is located
at the C-terminal loop of p75NTR (ECD juxtamembrane CRD4
region) in the vicinity of the residues Cys152, Gln148, Thr140 and
Val141, facing at the opposite side of the p75NTR/NGF interfacial
region. The ligand uses only one of its polar edges either 3-OH
or the substitution 21-OH functionalities to contact the protein
surface (Supplementary Figure 2).
Subsequently, we investigated the interactions of BNN27
with the complexed form of p75NTR with NGF through a long
exploratory MD run (200 ns). Interestingly, BNN27 initially
located at site 5, migrated toward the p75NTR/NGF interfacial
region and stabilized interactions with crucial contact residues
of the complex (NGF Arg114A and p75NTR Cys136) (Figure 2;
Supplementary Figure 3). The remaining BNN27 molecules,
which were initially placed in the vicinity of the predicted binding
sites of p75NTR, developed random contacts with the complex
surface.
In a further step, we investigated the behavior of BNN27
with the heterodimeric p75NTR/proNGF 2:2 complex mutated
as described above (see Materials and Methods) to model
NGF homodimer. An ensemble of seven BNN27 molecules
were placed in the neighboring of the predicted binding sites
at the p75NTR/proNGF modified complex (data not shown)
and MD simulations investigated the possibility of BNN27
to spontaneously penetrate the complex surface from the
FIGURE 2 | Superimposition of representative MD simulations
snapshots of BNN27 bound at p75NTR/NGF 2:1 and at p75NTR/mutated
proNGF 2:2 complexes. Superimposed frames of MD simulations performed
at the p75NTR/NGF 1:2 and p75NTR/mutated proNGF 2:2 complexes with
BNN27. The steroid analog (in yellow) is spontaneously inserted at the CRD4
interfacial region of p75NTR (in blue)/NGF (in pink). At the modified p75NTR (in
brown)/mutated proNGF (in green), BNN27 (in red) spontaneously penetrates
at the interfacial region located at p75NTR CRD1-CRD2 junction.
bulk water. Interestingly, simulations revealed the unprompted
insertion of BNN27 already within the initial 40 ns, and its
favorable harboring throughout the rest of the simulation time in
an interfacial region located at the p75NTR CRD1-CRD2 junction
coinciding with the described NGF epitope as site I/patch 2
by (He and Garcia, 2004) (Figure 2). Specifically, BNN27 is
“sandwiched” between the lipophilic residues NGF Phe49B and
NGF Trp99B and contacts through H-bond with its 3-OH group
p75NTR Asp41 which additionally forms a salt bridge with NGF
Lys88A, a conserved interaction also observed in both symmetric
and asymmetric crystal structures of p75NTR (Supplementary
Figure 4).
In the symmetrical p75NTR/proNGF 2:2 complex the flexible
hairpin loop L2 at the top of the mature region of proNGF dimer
(residues 40–50) adopts an “open” state (Feng et al., 2010) which
was not affected upon mutation to model human NGF. This
conformation most probably favors the spontaneous insertion of
the BNN27 ligand at the site I, patch 2 interfacial region located
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at the top of the complex. Moreover, (Pimenta et al., 2014) have
proposed that the motion of the L2 loop influences the motion of
the NGF L3 loop located at the lower part of the dimer (residues
60–70) and this may contribute to the unsuccessful approach
of BNN27 to the hot spot identified from the MD run of the
asymmetric complex of p75NTR with NGF, in which the top NGF
region adopts a more closed conformation.
BNN27 Binding to p75NTR Receptors
Activates Downstream Signaling in MEF
Cells
We tested the effectiveness of BNN27 to promote the interaction
of p75NTR with its effector proteins RhoGDI and RIP2, the
two major signaling pathways activated by neurotrophin binding
to p75NTR (Khursigara et al., 2001; Yamashita and Tohyama,
2003). It is well documented that NGF induces the release of
the intracellularly attached to the receptor, RhoGDI protein,
which in its turn interacts with RhoA, blocking the activity
of the latter (Yamashita and Tohyama, 2003). Moreover, the
release of RhoGDI upon NGF-induced activation of p75NTR was
recently shown to be facilitated by the recruitment of another
intracellular interactor, the RIP2 protein (Charalampopoulos
et al., 2012). To investigate the effects of BNN27 on these specific
signaling properties of p75NTR receptor, we used primary MEFs,
endogenously expressing RhoGDI and RIP2 but lacking p75NTR.
Transiently transfected with p75NTR plasmid MEF cell cultures
were either untreated or incubated with 1-100 nM BNN27 for
30 min, then cell extracts were immunoprecipitated with an anti-
p75NTR antibody and the immunoprecipitates were analyzed by
immunoblotting using an anti-RhoGDI antibody. As expected,
endogenous RhoGDI was found to be associated with p75NTR
in transfected MEF cells and this interaction was decreased
by NGF (Figure 3A). BNN27 similarly to DHEA and NGF
induced the release of RhoGDI from p75NTR (Figure 3A) and
the subsequent significant decline of RhoA activity (Figure 3B).
This effect of BNN27 on RhoGDI release was clearly observed
at the concentrations of 10 and 100 nM, and less at 1 nM
(Figure 3C). Interestingly, the steroid Estradiol (E2) was found
to be ineffective (Figures 3A,B), indicating a steroid structure-
specific effect.
Activation of p75NTR signaling also involves the ligand
dependent recruitment to the receptor cytoplasmic domain of
specific cytoplasmic signaling molecules, such as RIP2. Thus,
we examined whether p75NTR in transfected MEF cells could
interact with RIP2 in response to BNN27. Binding of the
compound to p75NTR elicited the recruitment of RIP2 to the
receptor (Figure 3D), effect not shown with E2. NGF and DHEA
treatment also induced the interaction between p75NTR and RIP2
in transfected MEF cells (Figure 3D).
To further identify the domains of p75NTR receptor interacting
with BNN27, we examined the efficacy of BNN27 in recruiting
the effector protein RIP2 on two p75NTR mutants, p75NTR1ECD
lacking the entire ECD, and p75NTRC257A lacking the ability to
mediate RIP2 recruitment due to its low dimerization capacity
(Vilar et al., 2009). Our findings show that the ECD of p75NTR and
its dimerized conformation are necessary for BNN27 to facilitate
recruitment of RIP2 on p75NTR receptors (Figure 3E), supporting
our findings from the competition binding assays (Figure 1A).
BNN27 Prevents Mouse Primary
Cerebellar Granule Neurons from
Apoptosis, in a p75NTR-Dependent
Manner
The exact factors that enable p75NTR to switch between its
two opposite roles, mediator of pro-survival or apoptotic
signaling, have not been identified with certainty. Indeed,
p75NTR receptor can trigger variant cellular effects due to its
multiple signaling properties in a cell-context specific manner,
tempospatial differences in ligand availability or co-receptors
expression (Bronfman and Fainzilber, 2004; Vicario et al., 2015).
We tested the p75NTR-mediated effects of BNN27 in apoptotic
signaling using the p75NTR-positive CGNs, lacking the expression
of NGF high-affinity TrkA receptors. Consistent with previous
reports (Minichiello and Klein, 1996; Courtney et al., 1997;
Koshimizu et al., 2010), we confirmed that our CGNs cultures
express p75NTR, TrkB, the selective receptor for BDNF, but not
TrkA (Figure 4A). Furthermore, a weak but specific TrkC-
positive immunoreactivity was also shown in CGNs (data not
shown). BNN27 is activating both TrkA and p75NTR but not
TrkB or TrkC receptors (Pediaditakis et al., 2016). Thus, CGNs
represent a suitable model of neuronal cells to investigate the
actions of BNN27 specifically through p75NTR receptors.
We examined the ability of BNN27 to control apoptotic
cell death, of primary cultures of CGNs induced by serum
deprivation, and assessed by TUNEL assay. Pilot time-course
experiments revealed that the maximum apoptotic cell death
upon serum deprivation was occurring at 24 h (data not shown).
Thus, CGNs cultures isolated from wt and p75NTR-KO mice
were exposed to 100 nM BNN27 for 24 h, fixed and stained
for TUNEL assay (indicator of late-apoptotis) and the neuronal
marker b-III tubulin (Figure 4B). BNN27 effectively protected
wt-CGNs from apoptosis. Interestingly, the protective effects of
both NGF and of BNN27 were completely abolished in p75NTR –
KO-CGNs (Figure 4C). On the contrary, the anti-apoptotic effect
of BDNF was still present in p75NTR –KO-CGNs, most probably
mediated by the TrkB receptors. These findings suggest that
the neuroprotective actions of BNN27 in CGNs are exclusively
mediated by p75NTR, mimicking the well-described pro-survival
effects of NGF in this neuronal type.
BNN27 Propagates p75NTR-Depenedent
Pro-survival Signaling in Primary
Cerebellar Granule Neurons
The p75NTR receptor has been shown to engage multiple
signaling pathways, including the cell death-related JNK and
Caspase-3 (Bhakar et al., 2003), as well as the pro-survival
NFκ B, in association with its upstream TRAF6 and RIP2 effector
proteins (Khursigara et al., 1999, 2001).
Thus, we performed co-immunoprecipitation studies to assess
the effects of BNN27 in the above p75NTR related signaling
pathways in primary CGNs, starting with the recruitment of
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FIGURE 3 | BNN27 activates p75NTR signaling. (A) BNN27 induced the release of RhoGDI from p75NTR in mouse embryonic fibroblasts (MEF cells). MEF cells
were transfected with the plasmid cDNA of p75NTR and control plasmid (Mock). Transfectants were exposed for 30 min with BNN27 (100 nM), DHEA (100 nM), NGF
(100 ng/ml), or Estradiol (E2) (100 nM), and lysates were immunoprecipitated with p75NTR-specific antibodies, then immunoblotted with antibodies against RhoGDI.
Total lysates were analyzed for p75NTR expression by immunobloting. Fold change was calculated by densitometric scanning of RhoGDI (beads) signals normalized
to RhoGDI (lysates) levels. Results are representative of three independent experiments. (B) Regulation of RhoA activity by BNN27 in MEF cells. Constitutively active
RhoA protein (provided by the kit manufacturer) was used as positive control. Results are expressed as the mean of triplicate measurements ± SEM normalized to
control. ∗P < 0.05 versus control. (C) BNN27 induced the release of RhoGDI from p75NTR in a dose-dependent manner. MEF cells were transfected with the
plasmid cDNA of p75NTR and control plasmid (Mock). Transfectants were exposed for 30 min with various concentrations of BNN27 (1, 10, or 100 nM), or NGF
(100 ng/ml), and lysates were immunoprecipitated with p75NTR-specific antibodies, then immunoblotted with antibodies against RhoGDI. Total lysates were analyzed
for p75NTR expression by immunobloting. Fold change was calculated by densitometric scanning of RhoGDI (beads) signals normalized to RhoGDI (lysates) levels.
Results are representative of three independent experiments. (D) BNN27 induced the association of p75NTR with its effectors RIP2 in MEF cells. MEF cells were
transfected with the plasmid cDNA of p75NTR. Transfectants were exposed for 30 min to vector (Control), BNN27 (100 nM), DHEA (100 nM), NGF (100 ng/ml) or
Estradiol (E2) (100 nM), and lysates were immunoprecipitated with p75NTR-specific antibodies, and then immunoblotted with antibodies against RIP2. Total lysates
were analyzed for p75NTR expression by immunobloting. Fold change was calculated by densitometric scanning of RIP2 (beads) signals normalized to RIP2 (lysates)
levels. Similar results were obtained in three independent experiments. (E) Structure-function relationships in the interaction between BNN27 p75NTR. MEF cells were
transfected with the plasmid cDNAs of p75NTR wt or p75NTR mutants that lack the entire Extracellular Domain (1ECD) or p75C257A and interactor RIP2.
Transfectants were exposed for 30 min to vector (Control), BNN27 (100 nM), DHEA (100 nM), NGF (100 ng/ml) or E2 (100 nM), and lysates were immunoprecipitated
with p75NTR-specific antibodies, and then immunoblotted with antibodies against RIP2. Total lysates were analyzed for p75NTR expression by immunobloting. Fold
change was calculated by densitometric scanning of RIP2 (beads) signals normalized to RIP2 (lysates) levels. Similar results were obtained in three independent
experiments.
RIP2 to p75NTR, an important condition for the activation
of pro-survival NFκB pathway. BNN27 rapidly and in an
NGF/DHEA-similar manner, induced RIP2 recruitment to
p75NTR in CGNs (Figure 5A). In previous studies we have shown
that ligand-dependent RIP2 recruitment is structurally linked
to the release of RhoGDI protein, since they both compete for
the same amino acid residues in the Death Domain (DD) of
p75NTR receptor (Charalampopoulos et al., 2012). Based on this
observation, we tested the ability of BNN27 to mimic NGF and
DHEA in releasing RhoGDI from p75NTR receptor. As suggested
by the RIP2 recruitment experiments, BNN27 was also effective
to release RhoGDI from the DD of p75NTR receptor (Figure 5B).
We finally investigated the ability of BNN27 to induce
phosphorylation of pro-death c-jun kinase (JNK) in cultured
CGNs, isolated from wt and p75NTR-KO mice. As expected, levels
of active JNK were elevated in CGNs cultured under serum-
deprived conditions. Incubation with 100 nM BNN27 for 30 min
decreased the activity of JNK by 80% in the aforementioned
conditions (Figure 5C). The response to BNN27 was p75NTR-
dependent, since it was fully abolished in CGNs, isolated from
p75NTR-KO mice (Figure 5C). Furthermore, BNN27 attenuated
the activation/cleavage of pro-apoptotic Caspase-3 in CGNs
isolated from wt mice, (in agreement with the TUNEL assay
results, Figures 4B,C), an effect which was also absent in CGNs
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FIGURE 4 | BNN27 protects against apoptosis primary mouse cerebellar granule neurons. (A) Neurotrophin receptors expression in cerebellar granule
neuron cultures. Cerebellar granule neurons at 1 DIV express the pan-neurotropic receptor p75NTR and TrkB, the selective receptor for BDNF, but they do not
express TrkA. HEK293 cells transfected with the appropriate cDNA of neurotrophin receptors were used as positive controls. (B) Cell death in response to BNN27
treatment was assessed in p75NTR wt (up-right) and p75NTR knockout (KO) (down-right) cerebellar granule neurons (CGNs), identified by b-III tubulin immunostaining
(green), using the TUNEL method (red). White arrows indicate TUNEL positive cells that do not express β-III tubulin (red nucleus) and thus represent a non- specific
cell population whereas yellow arrows represent TUNEL and β-III tubulin double-positive cells (yellowish nucleus), which is the cell population that was count. Scale
bar: 50 µm. (C) Quantification of TUNEL positive neurons CGN cultures (p75NTR wt, left and p75NTR KO, right) after 16 h serum withdrawal, incubation with BNN27,
NGF or BDNF. Results are expressed as the mean ± SEM. (corrected to control) of three independent experiments, each performed in triplicate. ∗P < 0.05 versus
control (Student’s t-test).
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FIGURE 5 | BNN27 decreases cell death signaling in primary mouse cerebellar granule neurons. (A) Co-immunoprecipitation of RIP2 with p75NTR in CGNs
isolated from p75NTR wt mice. Incubation of CGNs for 20 min with BNN27, DHEA and NGF induce the recruitment of RIP2 from p75NTR. Fold change was
calculated by densitometric scanning of RIP2 (beads) signals normalized to RIP2 (lysates) levels. Similar results were obtained in three independent experiments.
(B) Co-immunoprecipitation of RhoGDI with p75NTR in CGNs isolated from p75NTR wt mice. Incubation of CGNs for 30 min with BNN27, DHEA and NGF induce the
release of RhoGDI from p75NTR. Fold change was calculated by densitometric scanning of RhoGDI (beads) signals normalized to RhoGDI (lysates) levels. Similar
results were obtained in three independent experiments. (C) Levels of phosphorylated c-jun kinase (p-JNK) in CGNs isolated from wt and p75NTR KO mice. BNN27,
DHEA or NGF Fold change was calculated by densitometric scanning of phospho-JNK signals normalized to total JNK levels. Results are representative of three
experiments. (D) Activated Caspase-3 in CGNs, isolated from wild-type (WT) and p75NTR knockout (KO) mice. After 16 h serum withdrawal treatment. Fold change
was calculated by densitometric scanning of cleaved-Caspase-3 signals normalized to actin levels.
from p75NTRKO-mice (Figure 5D). In addition, DHEA, similarly
to BNN27, is not affecting JNK or Capsase-3 activity in p75KO-
derived CGNs, clearly indicating that it also acts exclusively via
p75NTR. These results confirm our previous observations that
BNN27 and DHEA selectively activate the p75NTR receptor but
not TrkB (Pediaditakis et al., 2015, 2016).
DISCUSSION
The low-affinity receptor of NGF, p75NTR, was firstly identified
in Chao et al. (1986) and Johnson et al. (1986), as a member
of the TNF receptors superfamily. It bears a DD, affording
its function as a death receptor. Many neuronal cells during
nervous system development or after injury are undergoing
apoptosis through activation of p75NTR in a cell-autonomous
or non-autonomous manner with elevation of its expression
(reviewed in Ibáñez and Simi, 2012; Meeker and Williams,
2015). Interestingly, p75 exon-3 knockout mice, showed reduced
cell death in the retina (Lee et al., 1992). The pro-death
functions of p75NTR are mainly activated by immature forms of
neurotrophins (pro-neurotrophins) and parallel cross-talk with
another membrane co-receptor, sortilin (Nykjaer et al., 2004).
Mature neurotrophins can also induce p75NTR-dependent cell
death, but these actions oppose their effects through their high-
affinity specific receptors, the pro-survival Trk receptors. It
thus appears that neurotrophin signaling properties are rather
complicated and each neurotrophin receptor presents a context-
dependent activity profile. Indeed, even if the knowledge on the
diverse functions of this receptor is still weak, p75NTR-mediated
actions include cell survival or death, regulation of neuronal
precursor proliferation and inhibition of neurite outgrowth,
synaptic pruning and long-term depression, depending upon
the co-expression of Trk receptors, co-receptors like sortilin or
Nogo, various intracellular signaling adaptor proteins like RIP2,
TRAF6 or RhoGDI, and finally a plethora of potential ligands,
like immature and mature neurotrophins, Aβ peptide, or myelin
derivatives (reviewed by Lu et al., 2005; Schor, 2005; Meeker
and Williams, 2015). The tempo-spatial expression of p75NTR
receptors in many CNS structures as the basal forebrain, striatum
and cerebellum in normal and pathological conditions, has
highlighted the importance of this receptor in neurodegenerative
conditions. During the last decade p75NTR has emerged as
a potential therapeutic target for many neurodegenerative
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FIGURE 6 | Schematic illustration of the pro-survival effects of BNN27 in a p75NTR-mediated manner in primary mouse cerebellar granule neurons.
BNN27 activates p75NTR receptors, leading to the control of pro-survival RhoGDI and RIP2 effectors while in parallel attenuating the activation of pro-apoptotic JNK
and Caspase-3 factors.
disorders (reviewed in Shu et al., 2015). Various pharmacological
strategies were specifically targeting p75NTR, aiming to constrain
its multiple responses in a cell-context manner. Endogenous
neurotrophins are lacking a favorable pharmacokinetic profile,
because of their polypeptidic nature and their inability to
penetrate the BBB. Therefore efforts for developing small
molecules have been recently undertaken (reviewed in Longo and
Massa, 2013). In the present study we propose a highly lipophilic,
BBB-permeable synthetic steroid as a potential lead molecule to
develop p75NTR receptor ligands.
Our findings provide biochemical and biophysical evidence
that the synthetic 17-spiroepoxy derivative of neurosteroid
DHEA, BNN27, effectively interacts with p75NTR receptors.
BNN27 aims at surpassing the limited clinical value of DHEA
and its profile as a non-specific multi-receptor activator and
a precursor for the biosynthesis of androgens and estrogens
(Calogeropoulou et al., 2009). Indeed, neurosteroids DHEA
and DHEA-S, produced within the brain, effectively protect
neurons against apoptosis (Charalampopoulos et al., 2004).
Surprisingly, DHEA was shown to bind and activate all
invertebrate and vertebrate Trk neurotrophin receptors as well
as the p75NTR pan-neurotrophin receptor in various neuronal
cell types, representing most probably an ancestral in evolution
neurotrophic factor (Lazaridis et al., 2011; Pediaditakis et al.,
2015). However, the potential clinical use of DHEA, as a long-
term neuroprotective therapeutic is compromised by its multiple
secondary effects via its binding to various steroid (estrogen
receptors alpha and beta, ARs) and neurotransmitter receptors
(GABAA, NMDA, and sigma1 receptors) (Charalampopoulos
et al., 2008). Last but not least, DHEA holds a central role
in steroidogenesis, as a precursor steroid in the biosynthesis
of androgens and estrogens (Charalampopoulos et al., 2008).
It is of note that recent studies associate DHEA to an
increased prevalence of hormone-dependent tumors, particularly
to genetically predisposed patients (Fourkala et al., 2012). Thus,
BNN27 represents a more specific, with potentially less secondary
effects neuroprotective agent, showing specific binding to only
TrkA and p75NTR receptors, and being deprived of estrogenic
and androgenic actions, unable to bind to and activate steroid
receptors (Calogeropoulou et al., 2009; Pediaditakis et al., 2016).
We have recently shown that in neuronal populations
expressing both TrkA and p75NTR, BNN27 is exhibiting TrkA-
mediated, pro-survival effects, acting as a NGF mimetic, without
affecting TrkB or TrkC receptors (Pediaditakis et al., 2016).
However, the study of the effects of BNN27 through the p75NTR
receptor was challenging in these neuronal cell types, since
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p75NTR may act synergistically, antagonistically or independently
of TrkA receptors. In the present study, we sought to explore the
decoupling of the effects of BNN27 through TrkA and p75NTR
receptors, using neuronal cells expressing only one of these
receptors, p75NTR.
Competition binding assays in cells transfected with p75NTR
and lacking Trk receptors, pull-down experiments with
recombinant p75NTR and PEG-immobilized BNN27, as well
as STD-NMR studies and in silico studies clearly show that
BNN27 is capable to physically interact with p75NTR, and this
interaction requires the ECD of the receptor. Furthermore, STD-
NMR revealed that the presence of NGF at the p75NTR/BNN27
solution induces an enhancement of BNN27 interactions
with the formed p75NTR/NGF complex. Molecular dynamic
simulations confirmed the interaction of BNN27 with the
p75NTR receptor as a monomer probing the juxtamembrane
CRD4 region as the most accessible for BNN27. Moreover, in
silico studies revealed that BNN27 interacts fruitfully with the
complexes p75NTR/NGF 1:2 and p75NTR/proNGF 2:2 mutated
to model human-NGF homodimer. Specifically, BNN27 was
spontaneously inserted at the interfacial region of p75NTR/NGF
asymmetric complex close to the juxtamembrane region
while in the case of the symmetric p75NTR/mutated proNGF
complex the ligand was accommodated at a hydrophobic
pocket (site I, patch 2 region) located at p75 CRD1-CRD2
junction. Thus, molecular dynamics simulations confirmed
the interaction of BNN27 with p75NTR:NGF complex as was
evidenced by STD-NMR data. The proposed hot spots are not
conclusive given the limitations imposed by the flexibility of
the NGF loops L2 and L3, however, in the absence of additional
crystallographic data they could assist the efforts toward
optimized ligands.
As a cellular system to assess the p75NTR-dependent effects of
BNN27, we have chosen the primary neuronal cultures of mouse
CGNs. These neurons express p75NTR, TrkB and TrkC, but not
TrkA. It is well described by many studies (Minichiello and Klein,
1996; Courtney et al., 1997), that BDNF and NT-3, ligands for
TrkB and TrkC respectively, protect CGNs against toxic stimuli.
Additionally, proBDNF acts as a p75NTR- mediated apoptotic
signal in this type of neurons (Koshimizu et al., 2010).
Surprisingly, in addition to promoting apoptosis, p75NTR
is known to also favor neuronal survival. Indeed, the ability
of p75NTR to enhance neuronal or glial survival is shown by
multiple studies (DeFreitas et al., 2001; Hannila and Kawaja,
2005; Wehner et al., 2016), been associated to the activation
of pro-survival transcription factor NFκB (Hamanoue et al.,
1999). Interestingly, binding of RIP2 to p75NTR leads to NFκB
activation (Khursigara et al., 2001). Recent studies have also
indicated that RIP2 recruitment facilitates the release of RhoGDI
by p75NTR, competing for common residues at the DD of
the receptor (Charalampopoulos et al., 2012). The release of
RhoGDI blocks the down-stream RhoA protein. The Rho family
of GTPases belongs to the Ras superfamily of low molecular
weight (21 kDa) guanine nucleotide binding proteins, and is
associated to pro-apoptotic processes (Dubreuil et al., 2003;
Sanno et al., 2010).
Genetic and pharmacological studies have documented the
different signaling properties of the p75NTR receptor, depending
upon differences in proteolytic cleavage of the receptor (Vicario
et al., 2015), in intracellular machinery (Lu et al., 2005) and in
co-expression of various co-receptors (Lee et al., 2001; Wang
et al., 2002; Knowles et al., 2009). More specifically in the CGNs
neuronal population, ligand-dependent activation of p75NTR
was unable to induce cell death, due to a strong activation of
pro-survival NFκB that prevailed the apoptosis signal. On the
contrary, hippocampal neurons exhibited increased apoptosis
upon p75NTR activation because of their inability to adequately
activate NFκB (Vicario et al., 2015). In the present study, we
describe the efficacy of BNN27 to prevent apoptosis of CGN
neurons, in a p75NTR-mediated manner. These neuroprotective
effects of BNN27 are afforded by the activation of RIP2 and
the concomitant release from p75NTR receptor of RhoGDI, the
blockade of down-stream pro-apoptotic RhoA and the activation
of pro-survival transcription factor NFκB.
In addition to the pro-survival signals that BNN27 induces
through p75NTR receptors, it inhibits in parallel specific
pro-apoptotic signals. Previous studies have reported that
overexpression of p75NTR in primary cortical neurons, PC12
cells, or glioma cells leads to the activation of both JNK
kinase and apoptotic Caspase-3 (Gu et al., 1999; Wang et al.,
2001; Harrington et al., 2002; Bhakar et al., 2003). We
now report that BNN27 is effective in attenuating both the
phosphorylation/activation of the pro-apoptotic JNK and the
cleavage of apoptotic executor Caspase-3, thus enhancing CGNs
survival in parallel with its beneficial effects on pro-survival
signaling. The inhibitory effect of BNN27 on pro-apoptotic
JNK and Caspase-3 is mediated by p75NTR receptors since it
is totally abolished in CGNs, isolated from p75NTR-KO mice.
These findings strongly suggest that specific neurons that express
p75NTR but not TrkA, respond to BNN27 by enhancing their
pro-survival signaling upon growth factors derivation, and this
effect is dependent on p75NTR expression (Figure 6). On the
other hand, BDNF induces survival in the same p75NTR-lacking
neurons, supporting our interpretation that BDNF, presumably
acts via the TrkB receptor.
The p75NTR receptor emerged recently as a new therapeutic
target for various conditions, including neurodegenerative
diseases, brain trauma and neuronflammation. Indeed,
identification through in silico screening of the first non-
peptide small-molecule ligands modulating p75NTR signaling,
generated several alternative strategies, mainly elucidated from
other receptors studies (reviewed in Longo and Massa, 2013).
These new synthetic ligands target the induction or inhibition
of dimerization/activation of p75NTR, affecting its membrane
conformation. It is worth noticing that p75NTR is a multidomain,
multifunctional receptor, interacting with a plethora of ligands,
most probably through different domains, some of which may
principally mediate binding, whereas others recognize specific
ligand domains, differentially affecting receptor conformation.
The limited size of small molecules restrain their ability to fully
emulate the multiple set of multi-domain receptor interactions
of polypeptidic, native neurotrophins. Our synthetic compound,
BNN27, represents a new class of potential ligands for p75NTR
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receptor, with agonist actions, depending upon the cell
context. Its lipophilic structure offers important pharmacological
advantages, conferring BBB penetration (Bennett et al., 2016).
Additionally, it easily integrates into the membrane lipophilic
environment, reaching very important trans-membrane residues
of the receptor, including the Cysteine-257, known as the residue
with a pivotal role for the dimerization of the receptor (Vilar
et al., 2009). The presence of cell-specific membrane co-receptors
(TrkA and others) may locally modify the functions of BNN27
through p75NTR and, consequently, the effects of p75NTR-
mediated signaling, allowing a broad range of actions, potentially
distinct from these of native neurotrophins. The knowledge
emerging from studies on the interaction of BNN27 with p75NTR
may facilitate the design of molecules with tailored therapeutic
properties, developing drugable disease-specific compounds.
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